Blog
NETRF Announces $2.5 Million in Research to Advance the NETs
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
February 1, 2019
No Comments
New grants to explore CAR-T, PRRT, a vaccine for NETs and other innovative approaches.
As we get ready to welcome 2019, we want to thank those who helped NETRF make 2018 so memorable. This year, with your help, we climbed mountains, reached new heights, and are ready for the next part of our journey to find better treatments and cures.
In October 2017, Haillie’s stepmother, Esther— who hadn’t been feeling well—was having a lot of doctor appointments and tests.
Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world.
If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them?
Many patients and families facing a neuroendocrine tumor (NET) diagnosis wonder if they inherited the disease from their parents or if they can pass it
What is the difference between a pancreatic neuroendocrine tumor and a pancreatic tumor? A few high profile celebrities, Aretha Franklin and Steve Jobs, have died
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama